接受美容植入物的女性未来患乳腺癌的几率低于一般人群。我们假设植入物异物反应可以诱导局部保护性抗癌免疫监视。我们扩展了之前的发现，该发现显示接受乳房植入的女性对某些乳腺癌蛋白的抗体反应升高。从接受首次隆胸（初次隆胸，IN）和修正隆胸（隆胸）的女性中收集血液样本和乳房组织。暴露，即）。收集血清并通过酶联免疫吸附测定（ELISA）对常见乳腺癌蛋白的抗体水平进行定量。对乳腺组织样本进行 RT-PCR，以量化 IN 和 IE 之间的免疫相关基因表达水平。进行大量 RNA 测序，以确定 IN 与 IE 乳房中差异表达的基因和改变的信号通路。总共招募了 188 名患者（117 名 IN，71 IE）。数据表明，与 IN 患者相比，IE 患者的 MUC-1、ER 和乳房珠蛋白 A 抗体水平较高。与 IN 乳腺组织相比，IE 中的 MUC-1 表达更高。 RNA-seq 分析表明 IE 乳腺组织中 B 细胞激活和发育、Th2 相关基因、T 细胞激活、趋化因子和雌激素反应的通路上调。这是第一项证明种植体周围炎症延伸到种植体之外的研究胶囊至乳腺实质。接受乳房植入的女性乳房实质中的 B 细胞更加活跃，对乳腺癌抗原的抗体反应也增强。版权所有 © 2024 美国整形外科医生协会。

Women with cosmetic implants have lower rates of future breast cancer than the general population. We hypothesized the implant foreign body response could induce a local protective anti-cancer immunosurveillance. We expanded on our previous finding which showed women with breast implants have elevated antibody responses to certain breast cancer proteins.Blood samples and breast tissue were collected from women undergoing first time breast augmentation (implant-naive, IN) and revision breast augmentation (implant-exposed, IE). Sera were collected and antibody levels to common breast cancer proteins were quantified by enzyme-linked immunosorbent assay (ELISA). RT-PCR was performed on breast tissue samples to quantify immune-related gene expression levels between IN and IE. Bulk RNA sequencing was performed to identify differentially expressed genes and altered signaling pathways in the breasts of IN versus IE.In total, 188 patients were recruited (117 IN, 71 IE). Data demonstrated that IE patients had higher levels of antibodies to MUC-1, ER, and mammaglobin A compared to IN patients. MUC-1 expression was found to be higher in IE compared to IN breast tissue. RNA-seq analysis demonstrated upregulated pathways in IE breast tissue for B cell activation and development, Th2 related genes, T cell activation, chemotactic factors, and responses to estrogen.This is the first study to demonstrate that peri-implant inflammation extends beyond the implant capsule to breast parenchyma. Women with breast implants have more activated B cells in the breast parenchyma and elevated antibody responses to breast cancer antigen.Copyright © 2024 by the American Society of Plastic Surgeons.